Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

Summary

This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 56 patients with Psoriasis.

Timeline

Start

2016-03-17

Primary completion

2018-02-28

Completion

2018-02-28

Outcome

Met primary endpoint

release “While the primary objectives of the study were achieved, advancing PRX003” prothena.com ↗

Drugs

Indications